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The growth of prostate cancer is largely dependent on male sex hormones called androgens, 
particularly testosterone. Many treatments for prostate cancer are aimed at dramatically reducing 
testosterone levels, thus slowing the growth of prostate cancer. However long-term androgen-
deprivation therapy (ADT) is associated with a number of side effects, including skeletal, cardiac and 
diabetic complications, hyperlipidemia, sexual dysfunction and hot flashes. The increased rate of 
bone loss, and associated increased risk of fractures, has been a long-standing clinical concern for 
long-term quality of life. Furthermore, the rate of bone loss and risk of developing fractures increases 
with the duration of ADT treatment. There has been recent interest in using bisphosphonates and 
other factors to decrease the risk of osteoporosis and bone fractures in patients undergoing ADT, 
but many of these treatments remain under study. 
Because of these side effects, as well as issues with the cost and efficacy of long-term ADT use, 
recent studies have compared the outcomes and side effects of intermittent androgen deprivation 
(IAD) to ADT. While the effect of IAD on long-term survival has been mixed, based on the patient 
population and disease stage examined, IAD has shown clear improvements in the quality of life 
among patients during treatment. Most notably, patients experience fewer sexual side effects and 
have improved quality-of-life during the off-treatment periods. To address the long-term effect of IAD 
treatment on skeletal health, Drs. Evan Yu and Tia Higano and colleagues in the Clinical Research 
Division, University of Washington and Seattle Cancer Care Alliance have examined the dynamics of 
bone mineral density (BMD) in men with non-metastatic, hormone-sensitive prostate cancer 
throughout a series of IAD treatment cycles. Fifty-six patients met the eligibility criteria for this study, 
including the presence of either locally advanced or biochemically recurrent prostate cancer 
following radical prostatectomy or radiation. Patients with biochemically recurrent prostate cancer 
were identified as those having at least two consecutive increases in the prostate-specific antigen 
(PSA) blood biomarker. Furthermore, men could not have detectable metastases. 
To assess the long-term effects of IAD on bone health, the authors measured BMD at the spine and 
left hip using dual-energy X-ray absorptiometry at baseline prior to treatment, at the completion of 
nine months of ADT, and following a period off treatment. Patients also received CT scans and 
lumbar spine X-rays to detect bone fractures. Patients were maintained off ADT treatment as long as 
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they maintained low serum PSA (1-4 ng/mL based on disease history). Patients whose PSA levels 
increased, a possible sign of greater disease burden, were treated using additional rounds of ADT 
until the development of resistance to androgen depletion (median: 5.5 years, range: 1.1 to 13.8+ 
years). The majority of patients (56-80%) experienced BMD losses during the first ADT treatment 
round, however they also experienced significant recovery during the off-treatment period. Further 
rounds of ADT had less of an effect on BMD, with an eventual stabilization of bone density over time 
to a level just below baseline. However, these results were heterogeneous between patients, 
possibly due to differences in recovery time for hormone and bone levels between patients. Despite 
this, patients did not experience any fractures, with the exception of a compression fracture reported 
by one patient after a fall from a ladder. By comparison, of a cohort of similar patients who received 
continuous anti-androgen treatment, 3.9% of patients experienced fractures following three years of 
ADT.  
This study demonstrates that prostate cancer patients with locally advanced or biochemically 
recurrent non-metastatic disease who receive IAD have generally stable bone health and are not at 
increased risk for bone fractures. Together with previous studies showing that men with non-
metastatic, hormone-sensitive prostate cancer who are on IAD do not experience any significant 
increase in development of therapy resistance, this study suggests that IAD may be a clinically 
relevant treatment option for a defined subset of prostate cancer patients. A larger phase III trial of 
IAD versus continuous ADT would be beneficial to define bone health and fracture risk in individual 
patients during IAD, as well as verify that IAD has similar long-term effects on survival as ADT within 
men with locally advanced and nonmetastatic, hormone-sensitive prostate cancer. 
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Diagram of one full cycle of 
intermittent androgen deprivation 
followed by an off-treatment 
recovery period. DXA bone 
scans, as well as CT and X-rays, 
were completed throughout the 
study to monitor bone health and 
development of fractures. 
